JP2020203894A5 - - Google Patents

Download PDF

Info

Publication number
JP2020203894A5
JP2020203894A5 JP2020135954A JP2020135954A JP2020203894A5 JP 2020203894 A5 JP2020203894 A5 JP 2020203894A5 JP 2020135954 A JP2020135954 A JP 2020135954A JP 2020135954 A JP2020135954 A JP 2020135954A JP 2020203894 A5 JP2020203894 A5 JP 2020203894A5
Authority
JP
Japan
Prior art keywords
vector
cardiac
deletion
seq
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020135954A
Other languages
English (en)
Japanese (ja)
Other versions
JP7685737B2 (ja
JP2020203894A (ja
Filing date
Publication date
Priority claimed from JP2015553072A external-priority patent/JP6809789B2/ja
Application filed filed Critical
Publication of JP2020203894A publication Critical patent/JP2020203894A/ja
Priority to JP2022178566A priority Critical patent/JP2023025005A/ja
Publication of JP2020203894A5 publication Critical patent/JP2020203894A5/ja
Application granted granted Critical
Publication of JP7685737B2 publication Critical patent/JP7685737B2/ja
Priority to JP2025092726A priority patent/JP2025143268A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020135954A 2013-01-17 2020-08-11 疾患の治療または予防に用いるためのファクター1およびファクター2タンパク質、およびその阻害剤 Active JP7685737B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022178566A JP2023025005A (ja) 2013-01-17 2022-11-08 疾患の治療または予防に用いるためのファクター1およびファクター2タンパク質、およびその阻害剤
JP2025092726A JP2025143268A (ja) 2013-01-17 2025-06-03 疾患の治療または予防に用いるためのファクター1およびファクター2タンパク質、およびその阻害剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13151593 2013-01-17
EP13151593.4 2013-01-17
JP2015553072A JP6809789B2 (ja) 2013-01-17 2014-01-16 疾患の治療または予防に用いるためのファクター1およびファクター2タンパク質、およびその阻害剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015553072A Division JP6809789B2 (ja) 2013-01-17 2014-01-16 疾患の治療または予防に用いるためのファクター1およびファクター2タンパク質、およびその阻害剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022178566A Division JP2023025005A (ja) 2013-01-17 2022-11-08 疾患の治療または予防に用いるためのファクター1およびファクター2タンパク質、およびその阻害剤

Publications (3)

Publication Number Publication Date
JP2020203894A JP2020203894A (ja) 2020-12-24
JP2020203894A5 true JP2020203894A5 (cg-RX-API-DMAC7.html) 2025-02-04
JP7685737B2 JP7685737B2 (ja) 2025-05-30

Family

ID=47559322

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015553072A Active JP6809789B2 (ja) 2013-01-17 2014-01-16 疾患の治療または予防に用いるためのファクター1およびファクター2タンパク質、およびその阻害剤
JP2020135954A Active JP7685737B2 (ja) 2013-01-17 2020-08-11 疾患の治療または予防に用いるためのファクター1およびファクター2タンパク質、およびその阻害剤
JP2022178566A Pending JP2023025005A (ja) 2013-01-17 2022-11-08 疾患の治療または予防に用いるためのファクター1およびファクター2タンパク質、およびその阻害剤
JP2025092726A Pending JP2025143268A (ja) 2013-01-17 2025-06-03 疾患の治療または予防に用いるためのファクター1およびファクター2タンパク質、およびその阻害剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2015553072A Active JP6809789B2 (ja) 2013-01-17 2014-01-16 疾患の治療または予防に用いるためのファクター1およびファクター2タンパク質、およびその阻害剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022178566A Pending JP2023025005A (ja) 2013-01-17 2022-11-08 疾患の治療または予防に用いるためのファクター1およびファクター2タンパク質、およびその阻害剤
JP2025092726A Pending JP2025143268A (ja) 2013-01-17 2025-06-03 疾患の治療または予防に用いるためのファクター1およびファクター2タンパク質、およびその阻害剤

Country Status (16)

Country Link
US (1) US10369198B2 (cg-RX-API-DMAC7.html)
EP (2) EP3747457A3 (cg-RX-API-DMAC7.html)
JP (4) JP6809789B2 (cg-RX-API-DMAC7.html)
CN (6) CN111100197B (cg-RX-API-DMAC7.html)
CA (1) CA2898128A1 (cg-RX-API-DMAC7.html)
DK (1) DK2945642T3 (cg-RX-API-DMAC7.html)
ES (1) ES2986021T3 (cg-RX-API-DMAC7.html)
FI (1) FI2945642T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240623T1 (cg-RX-API-DMAC7.html)
HU (1) HUE068364T2 (cg-RX-API-DMAC7.html)
LT (1) LT2945642T (cg-RX-API-DMAC7.html)
PL (1) PL2945642T3 (cg-RX-API-DMAC7.html)
PT (1) PT2945642T (cg-RX-API-DMAC7.html)
RS (1) RS65553B1 (cg-RX-API-DMAC7.html)
SI (1) SI2945642T1 (cg-RX-API-DMAC7.html)
WO (1) WO2014111458A2 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111100197B (zh) * 2013-01-17 2024-11-15 汉诺威医学院 用于治疗或预防疾病的因子1蛋白、因子2蛋白及其抑制剂
EP4005585B1 (en) 2013-11-21 2024-03-27 The Brigham & Women's Hospital, Inc. Compositions and methods for treating right ventricular hypertrophy
EP3174550B1 (en) * 2014-08-01 2020-01-29 The Brigham and Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
US10435757B1 (en) 2016-06-15 2019-10-08 University Of South Florida Methods of measuring C19MC miRNA in a post-natal tissue and uses thereof
CN108802372B (zh) * 2018-06-19 2021-05-11 上海伦泽生物科技有限公司 检测人血清中内质网膜蛋白复合体亚单位10的试剂盒
AU2021211874A1 (en) 2020-01-21 2022-08-25 Boehringer Ingelheim International Gmbh Myeloid-derived growth factor for use in treating or preventing fibrosis, hypertrophy or heart failure
CN114149499B (zh) * 2020-09-07 2023-12-05 复旦大学附属华山医院 抗人emc10的单克隆抗体及其在治疗和/或预防肥胖症中的应用
CN114149498B (zh) * 2020-09-07 2023-12-05 复旦大学附属华山医院 抗人emc10的单克隆抗体在防治2型糖尿病中的应用
CN114149500B (zh) * 2020-09-07 2023-12-01 复旦大学附属华山医院 抗人emc10的单克隆抗体在制备治疗和/或预防脂肪肝的产品中的应用
AU2021405790A1 (en) 2020-12-23 2023-07-06 Boehringer Ingelheim International Gmbh Viral capsid proteins with specificity to heart tissue cells
WO2023283649A1 (en) * 2021-07-08 2023-01-12 Tenaya Therapeutics, Inc. Optimized expression cassettes for gene therapy
US20250333459A1 (en) 2022-06-03 2025-10-30 Boehringer Ingelheim International Gmbh Recombinant expression of myeloid-derived growth factor
WO2024052564A1 (en) 2022-09-08 2024-03-14 Boehringer Ingelheim International Gmbh Myeloid-derived growth factor for use in treating cardiogenic shock
WO2025047991A1 (en) 2023-09-01 2025-03-06 Boehringer Ingelheim International Gmbh Myeloid-derived growth factor for use in treating or preventing a liver disorder
WO2025073372A1 (en) 2023-10-05 2025-04-10 Boehringer Ingelheim International Gmbh Recombinant expression of myeloid-derived growth factor
WO2025120204A1 (en) 2023-12-06 2025-06-12 Boehringer Ingelheim International Gmbh Novel formulation comprising myeloid-derived growth factor
CN120738287A (zh) * 2025-07-03 2025-10-03 广州医科大学附属妇女儿童医疗中心 急性低灌注动物模型的构建方法及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
JP2002500502A (ja) 1996-06-11 2002-01-08 メルク エンド カンパニー インコーポレーテッド 合成c型肝炎遺伝子
EP0932676A2 (en) * 1996-09-13 1999-08-04 Sagami Chemical Research Center HUMAN PROTEINS HAVING SECRETORY SIGNAL SEQUENCES AND DNAs ENCODING THESE PROTEINS
JP2001506484A (ja) * 1996-09-13 2001-05-22 財団法人相模中央化学研究所 分泌シグナル配列を有するヒト蛋白質およびそれをコードするdna
DE69827021T2 (de) * 1997-01-29 2005-02-24 Cornell Research Foundation, Inc. An verschiedenen orten verabreichung von adenoviren-vektor zur induzierung von angiogenese
CA2374180C (en) 1999-05-26 2012-09-11 Marita Hiipakka Methods and materials for generating sh3 domains with tailored binding properties
DE60038740T2 (de) * 1999-06-02 2009-07-02 Genentech, Inc., South San Francisco Stimulierung oder hemmung von angiogenese und herzvaskularisierung
CA2381985A1 (en) * 1999-08-16 2001-02-22 Universita'degli Studi Di Siena Vegf-d and angiogenic use thereof
CA2416538A1 (en) * 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2002081681A1 (fr) * 2001-03-30 2002-10-17 Chugai Seiyaku Kabushiki Kaisha Nouvelle utilisation de la cytokine sf20
DE10119804A1 (de) * 2001-04-23 2002-10-24 Brahms Ag Entzündungsspezifische Peptide und deren Verwendungen
US7452968B2 (en) 2003-01-02 2008-11-18 University Of Southern California Secreted protein factor and cell membrane-bound splice variant
WO2004069173A2 (en) * 2003-01-31 2004-08-19 The Trustees Of The University Of Pennsylvania Methods for modulating an inflammatory response
US8486438B2 (en) 2004-01-29 2013-07-16 Brown University Methods for progenitor cell recruitment and isolation
CN101160055A (zh) * 2005-02-16 2008-04-09 莱蒂恩公司 慢病毒载体及其用途
US20080004232A1 (en) * 2006-05-09 2008-01-03 John Wilkins Characterization of c19orf10, a Novel Synovial Protein
EP1892248A1 (en) 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
EP2130547A1 (en) * 2008-06-06 2009-12-09 Giuliani International Limited IL-25 for use in the treatment of inflammatory diseases
CN102741288B (zh) * 2009-08-29 2015-08-19 Abbvie公司 治疗用dll4结合蛋白
US8735342B2 (en) 2010-01-27 2014-05-27 Neumedicines, Inc. Method for treating brain cancer using a novel tumor suppressor gene and secreted factor
KR20120095063A (ko) * 2011-02-18 2012-08-28 가톨릭대학교 산학협력단 IL-27로 유도된 p53을 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
CN111100197B (zh) * 2013-01-17 2024-11-15 汉诺威医学院 用于治疗或预防疾病的因子1蛋白、因子2蛋白及其抑制剂

Similar Documents

Publication Publication Date Title
JP2020203894A5 (cg-RX-API-DMAC7.html)
JP2022115876A5 (cg-RX-API-DMAC7.html)
JP2023025005A5 (cg-RX-API-DMAC7.html)
US8435535B2 (en) Fusion proteins of HIV regulatory/accessory proteins
JP2019526580A5 (cg-RX-API-DMAC7.html)
RU2012107671A (ru) Композиция для лечения инфекции вирусом гепатита в
JP6929272B2 (ja) 疾患処置のための方法
JP2024177497A5 (cg-RX-API-DMAC7.html)
JPWO2019156137A5 (cg-RX-API-DMAC7.html)
JP2020536489A5 (cg-RX-API-DMAC7.html)
JP2019521692A5 (cg-RX-API-DMAC7.html)
JP2020527167A5 (cg-RX-API-DMAC7.html)
JPWO2020205889A5 (cg-RX-API-DMAC7.html)
JP2021500880A5 (cg-RX-API-DMAC7.html)
JPWO2020223362A5 (cg-RX-API-DMAC7.html)
JPWO2020223356A5 (cg-RX-API-DMAC7.html)
JP2018516599A (ja) ポックスウイルス由来のプロモーターおよびそれを含むベクター
JP7642608B2 (ja) ハンタウイルス抗原性組成物
JP2020535203A5 (cg-RX-API-DMAC7.html)
JP2020536519A5 (cg-RX-API-DMAC7.html)
JPWO2020038473A5 (cg-RX-API-DMAC7.html)
CN117838832B (zh) Rbm25及其相关物质在抗病毒感染中的应用
JPWO2022010813A5 (cg-RX-API-DMAC7.html)
CN109306011A (zh) 靶向RyR2蛋白的胞内纳米抗体在制备抗心力衰竭药物中的用途
JPWO2022015418A5 (cg-RX-API-DMAC7.html)